Application of kelimycin in mycobacterium tuberculosis infection resistance

A technology of mycobacteria and carrimycin, applied in medical preparations containing active ingredients, antibacterial drugs, organic active ingredients, etc., can solve problems such as limited bactericidal effect, low cure rate, and poor patient compliance

Active Publication Date: 2016-04-20
SHANGHAI TONGLIAN PHARMA CO LTD
View PDF4 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these drugs have many adverse reactions, limited bactericidal effect, long course of treatment, usually more than 6 months, and poor patient compliance
Second-line anti-tuberculosis drugs (with antibacterial effect on Mycobacterium tuberculosis): capreomycin, ethionamide, p-aminosalicylic acid, cycloserine, ciprofloxac

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of kelimycin in mycobacterium tuberculosis infection resistance
  • Application of kelimycin in mycobacterium tuberculosis infection resistance
  • Application of kelimycin in mycobacterium tuberculosis infection resistance

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] "Example 1" acquisition and processing of Mycobacterium tuberculosis specimens

[0015] According to the provisions of the national standard WS288-2008 "Diagnostic Criteria for Pulmonary Tuberculosis" issued by the Ministry of Health, select patients with confirmed or highly suspected tuberculosis with clinical symptoms, signs, and chest imaging examinations. Collect about 2 mL of sputum, pleural effusion, cerebrospinal fluid, and pus samples from the selected patients, and add them to a 50 mL centrifuge tube with a screw cap. Add N-acetyl-L-cysteine ​​sodium hydroxide (NaOH-NALC) pretreatment solution equal to that of the sample, and vortex for 20 seconds. Let stand at room temperature for 18 minutes. Add PBS (pH6.8) to 40mL, centrifuge at 3000g for 20 minutes, then discard the supernatant and keep the precipitate. 2 mL of LPBS (pH 6.8) was added to prepare a suspension. The treated specimens were inoculated into medium for solid culture.

Embodiment 2

[0016] "Example 2" Isolation and Culture Identification of Mycobacterium Tuberculosis Specimen

[0017] 1. Preparation of culture medium:

[0018] The composition of the medium is shown in Table 1. Add each ingredient into distilled water according to the listed dosage, fully dissolve; boil for 30 minutes or 121 ℃ high pressure for 15 minutes.

[0019] Take fresh chicken eggs, wash them with tap water, scrub them with soapy water, and wipe them with 75% alcohol for disinfection after drying. Under aseptic operation, pour the egg liquid into a sterilized graduated enamel cup, stir and mix well, after filtering with sterilized gauze, take 1000mL and add it, mix well; add 20mL of 2% malachite green, mix well; Add 7mL of culture medium into a test tube (18mm×180mm), and put it in a steam incubator at 85°C for 50 minutes to solidify. Take the prepared culture medium in the tube at 5%, put it into 37°C for 48 hours, and carry out the sterility test; after passing the sterility te...

Embodiment 3

[0026] "Example 3" Carrimycin anti-mycobacterium tuberculosis activity test

[0027] 1. Absolute concentration method

[0028] 1) Anti-TB drugs

[0029] Carrimycin standard product: from China National Institute for the Control of Pharmaceutical and Biological Products; reference drugs: isoniazid and rifampicin are standard products from Sigma Company. Anti-tuberculosis drugs were formulated into mother solutions at a certain concentration, and then added to the culture medium in a certain amount to prepare the required dose (Table 2).

[0030] 2) Strain inoculation

[0031] The strains isolated from clinical specimens were confirmed as cultures of acid-fast bacteria by smear, diluted with normal saline containing 10% Tween 80, and compared with McFarland standard turbidimetric tubes (Guangdong Huankai Microbiology Technology Co., Ltd.), and prepared 10 -2 mg / mL bacterial liquid, inoculated in the medium containing the test drug.

[0032] Negative and positive controls wer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of kelimycin in mycobacterium tuberculosis infection resistance. The application comprises the following main steps: clinical first-line antitubercular drugs isoniazide and rifamycin are used as contrast, and the antimycobacterial activity of kelimycin is detected by adopting an absolute concentration method. The result indicates that the activity of kelimycin on clinically separated mycobacterium tuberculosis including drug-resistance bacteria is remarkably superior to those of the clinical first-line contrast drugs isoniazide and rifamycin, and novel application of kelimycin is expected to be developed in treatment of tubercle bacillus infected diseases.

Description

Technical field: [0001] The invention relates to the application of macrolide antibiotics in the treatment of Mycobacterium tuberculosis infection. technical background: [0002] Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis (MTB) infection, mainly involving the lungs, and is the single cause of the largest number of deaths among infectious diseases. Tuberculosis is more common in immunocompromised populations and is the most common opportunistic infection associated with AIDS. According to the report of the World Health Organization (WHO), there are 8 million to 10 million new cases of tuberculosis every year in the world, and 3 million to 4 million people die of tuberculosis, especially in developing countries. It is also predicted that about 1 billion people will be infected and 35 million people will die of tuberculosis in 2000-2020. At the same time, MTB drug resistance is increasing year by year, which will become a major threat to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61P31/06
CPCA61K31/7048A61P31/06A61K31/496Y02A50/30A61K9/0019A61K9/0053
Inventor 王以光姜洋赵小峰赫卫清
Owner SHANGHAI TONGLIAN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap